What Does Non-FDG Avid Mean on a Medical Report?

A “non-FDG avid” finding on a medical report means that a particular area of your body did not take up a significant amount of the radioactive sugar tracer used during a PET/CT scan. In practical terms, the spot in question did not light up the way active cancers, infections, or inflammatory processes typically do. That can be reassuring, but it is not automatically a clean bill of health. The reasons a lesion stays dark on a PET scan range from genuinely harmless to biologically important, and the distinction matters for what your doctor recommends next.

How FDG Works and What “Avid” Actually Means

FDG stands for fluorodeoxyglucose, a modified sugar molecule tagged with a tiny amount of radioactive fluorine. After it is injected into your bloodstream, FDG travels throughout the body and gets absorbed by cells that are hungry for energy. Cancer cells, inflamed tissue, and active infections all tend to burn through glucose faster than normal tissue, so they pull in more FDG and glow brighter on the scan. The tracer gets trapped inside those cells rather than being metabolized further, which is what makes it visible to the camera.

1SpringerLink (Digestive Diseases and Sciences). It’s Not What You Take Up, It’s What You Keep: How Discoveries from Diverse Disciplines Directed the Development of the FDG PET/CT Scan

When your report says a lesion is “FDG avid,” it means the tissue soaked up enough tracer to stand out against the background. “Non-FDG avid” is the opposite: the area looks about the same as or even dimmer than the surrounding normal tissue. Radiologists sometimes quantify this with a measurement called SUVmax, a number reflecting how much tracer concentrated in the hottest part of a lesion relative to the rest of your body. Studies looking at lung nodules and lymph nodes have found that values above roughly 2 to 4, depending on the site, start to raise suspicion for cancer, while values at or near background levels suggest the tissue is metabolically quiet.

2PubMed. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study

Why Some Cancers Do Not Light Up

The assumption behind FDG-PET is that cancer cells are metabolic furnaces burning glucose at high rates. That is broadly true, but not universally true. Some cancers run on different fuel or simply grow too slowly to stand out on the scan. The variability depends on factors like how many glucose-transporter proteins sit on the cell surface, how active the internal enzyme that traps FDG is, and whether the cancer cells have shifted to an alternative energy source.

3PubMed Central. FDG uptake in cancer: a continuing debate

Prostate cancer is one of the best-known examples. Rather than relying heavily on glucose, prostate tumors tend to burn fatty acids for energy. That metabolic quirk means a standard FDG-PET scan can miss prostate cancer entirely, even when the disease is advanced.

4PubMed. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer

Neuroendocrine tumors are another important category. These tumors vary widely in aggressiveness, and the low-grade varieties are frequently non-FDG avid. A prospective study following patients for ten years found that about half of low-to-intermediate grade neuroendocrine tumors did not show up on FDG-PET, while nearly all high-grade cases did.

5Journal of Nuclear Medicine. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT

Interestingly, being non-FDG avid in neuroendocrine tumors is often a good prognostic sign. A meta-analysis found that patients whose tumors were FDG-negative before receiving a specific type of radiation therapy had a disease control rate above 90%, compared to about 74% for those whose tumors lit up on FDG-PET.

6PubMed Central. Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis

Mucinous cancers present a different problem. These tumors produce large amounts of mucin, a gel-like substance that dilutes the number of actual cancer cells per unit volume. A study examining mucinous tumors found that FDG uptake correlated positively with how densely packed the cancer cells were but negatively with how much mucin the tumor contained. A mucinous tumor full of mucin and relatively few cancer cells can look entirely non-avid on PET, even though it is malignant.

7PubMed. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features

Other cancer types that commonly fly under FDG-PET’s radar include certain slow-growing lung adenocarcinomas that appear as ground-glass nodules on CT, carcinoid tumors, low-grade lymphomas, and some well-differentiated thyroid cancers.

8PubMed Central. False positive and false negative FDG-PET scans in various thoracic diseases

Non-FDG Avid Does Not Always Mean “Nothing There”

If you are reading your PET report and see “non-FDG avid,” you might assume the area is harmless. Often that is correct. A non-FDG avid lung nodule, for instance, frequently turns out to be scar tissue, a small area of old infection, or a benign growth. But a study of patients who had non-FDG avid pulmonary lesions found that in about a third of cases, the same whole-body PET/CT scan turned up at least one other new incidental finding elsewhere that needed follow-up.

9Clinical Imaging. New incidental findings, nature, and downstream healthcare costs in patients with a non-FDG-avid pulmonary lesion on whole-body FDG-PET/CT

That finding is a useful reminder: PET/CT is a whole-body scan, and the report you receive usually addresses every organ the camera captured, not just the area your doctor was originally worried about. A non-avid nodule in the lung does not guarantee the rest of the scan is unremarkable.

When the Scanner Itself Is the Reason

Sometimes a lesion is genuinely metabolically active but still appears non-avid because of technical limitations. The most common culprit is size. PET scanners have limited spatial resolution, and when a lesion is very small, its signal gets smeared out and averaged with the surrounding normal tissue during image reconstruction. This partial-volume effect means that a malignant nodule under about a centimeter can look deceptively quiet on the scan.

10Journal of Nuclear Medicine. Clinical Significance of Small Pulmonary Nodules with Little or No 18F-FDG Uptake on PET/CT Images of Patients with Nonthoracic Malignancies

Breathing is another technical issue, especially for lesions near the base of the lungs or in the dome of the liver. The PET portion of the scan collects data over several minutes, during which you are breathing normally. The CT portion, used to map anatomy and correct for tissue density, captures a single snapshot. If the two do not line up perfectly because the organ has shifted with breathing, the correction applied to the PET data can be slightly off, making a lesion appear less active than it really is.

11PubMed. Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source

Blood sugar at the time of your scan also matters. FDG competes with your body’s own glucose for entry into cells. If your blood sugar is elevated when the tracer is injected, normal glucose molecules crowd out FDG, and less tracer ends up in the tissues the radiologist is trying to evaluate. Research has confirmed that elevated blood glucose pushes FDG uptake downward, which is why imaging centers ask you to fast before the scan and will sometimes postpone it if your glucose is too high.

12PubMed Central. Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review

What Happens After a Non-FDG Avid Result

Your doctor’s response to a non-avid finding depends heavily on the clinical context. For someone being screened for recurrence of a known cancer, a non-avid area may simply be noted and watched. For a newly discovered lung nodule, a non-avid PET result can actually steer the team away from an invasive biopsy. A prospective study of patients with intermediate-to-high-risk lung nodules found that when the PET showed faint or no uptake, doctors changed their management plan in a meaningful number of cases, recommending observation instead of biopsy. In all of those watch-and-wait cases, the nodules either shrank or resolved on follow-up without further intervention.

13BMJ Respiratory Research. Biopsy decision for intermediate–high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study

For cancers being actively treated, a shift from FDG-avid to non-FDG avid between scans is generally encouraging. It suggests the treatment is suppressing the tumor’s metabolic activity. In lymphoma, for example, the distinction between avid and non-avid on an interim or end-of-treatment PET scan is a key decision point for whether to continue, change, or stop therapy. Researchers have identified specific tracer-uptake thresholds that help distinguish genuine disease progression from benign inflammation that can appear during or after treatment.

14Frontiers in Medicine. Differentiating lymphoma progression from benign lesions: features of incident FDG-avid foci on interim and end-of-treatment PET/CT

Still, the absence of FDG uptake does not replace the need for clinical judgment. If a lesion looks suspicious on CT imaging, if tumor markers in your blood are rising, or if your symptoms point to disease activity, your oncologist may recommend biopsy or additional imaging even though the PET is quiet. Non-avidity lowers the probability of aggressive cancer, but it does not eliminate it.

Alternative Tracers for Cancers FDG Misses

When a cancer type is known to be non-FDG avid, nuclear medicine has developed other tracers designed to find it. The two most prominent alternatives target prostate cancer and neuroendocrine tumors, respectively.

For prostate cancer, gallium-68 PSMA PET has become the preferred scan. PSMA, a protein heavily expressed on prostate cancer cells, is an entirely different target from glucose metabolism. A case report illustrating the contrast showed that a standard FDG-PET scan failed to detect prostate cancer that was clearly visible on a PSMA-PET scan.

15PubMed Central. FDG-PET Versus PSMA-PET: A Patient With Prostate Cancer

Interestingly, the two tracers can complement each other rather than simply replacing one another. In advanced prostate cancer, some tumor cells lose PSMA expression and become more glucose-hungry as they de-differentiate. In those cases, an FDG-PET scan can pick up disease that a PSMA scan misses. This “discordant” pattern, where one tracer sees lesions the other does not, has practical consequences for treatment selection: patients with FDG-avid but PSMA-negative disease may not benefit from PSMA-targeted therapy and need a different approach.

16Journal of Nuclear Medicine. The Use of FDG-PET in conjunction with PSMA-PET in Prostate Cancer

For neuroendocrine tumors, gallium-68 DOTATATE PET targets somatostatin receptors on tumor cells. Low-grade neuroendocrine tumors that are invisible to FDG tend to strongly express these receptors, making DOTATATE the superior scan for detecting them. A study directly comparing the two tracers confirmed that DOTATATE was more useful for clinical decisions in low-grade tumors, while FDG was more informative in high-grade ones.

17Journal of Nuclear Medicine. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors

When both tracers are used in the same patient, the mismatch between them carries prognostic information. Lesions that light up on FDG but not on DOTATATE (so-called discordant disease) tend to signal more aggressive biology and worse outcomes. The volume of that discordant disease is being investigated as a biomarker to help predict which patients will do poorly.

18PubMed Central. [18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study

Newer Tracers on the Horizon

One of the most talked-about developments in PET imaging targets a protein called fibroblast activation protein, or FAP. Unlike FDG, which relies on a tumor cell’s own glucose appetite, FAP-targeted tracers home in on the support cells that surround a tumor. These so-called cancer-associated fibroblasts form a major part of the tumor’s scaffolding and express FAP at high levels across a wide range of cancer types, including many that are traditionally non-FDG avid.

19PubMed Central. FAPI PET/CT Imaging-An Updated Review

Early results have generated excitement because FAPI-PET appears to detect certain tumors, particularly mucinous, hepatobiliary, and peritoneal cancers, with better clarity than FDG. The tracer also produces less background noise in the brain and liver, two organs where normal FDG uptake is very high and can obscure small metastases. Research is still in relatively early stages, and FAPI-PET is not yet standard practice in most hospitals. But for patients whose cancers consistently evade FDG detection, it represents a genuinely new approach rather than a minor tweak to existing technology.

Ground-Glass Lung Nodules and the Limits of PET

Ground-glass nodules on a CT scan are one of the most common situations where a non-FDG avid result creates uncertainty. These hazy-looking lung opacities can represent anything from a transient bit of inflammation to an early-stage lung adenocarcinoma. Many of them are small and metabolically sluggish, which means they fall below the PET scanner’s detection threshold even when they harbor cancer cells.

A study specifically looking at ground-glass nodules in patients with invasive lung adenocarcinoma found that SUVmax, along with the nodule’s size and location, was an independent predictor of whether the cancer was high-risk or low-risk. The researchers built a prediction model using these factors that performed well in both training and validation groups.

20Frontiers in Medicine. The role of (18)F-FDG PET/CT in identifying risk factors for ground-glass nodules in invasive lung adenocarcinoma

The takeaway here is that PET information is most useful when combined with other features on the CT scan. A non-FDG avid ground-glass nodule that is small, stable over time, and has benign-looking features on CT is quite likely harmless. A larger non-avid ground-glass nodule with worrisome CT characteristics may still warrant biopsy or surgical removal, PET result notwithstanding. Your radiologist and pulmonologist weigh all of these features together rather than making decisions based on FDG avidity alone.

Reading Your Own PET Report

PET/CT reports can be dense and intimidating, and the language around FDG avidity varies between institutions. You may see phrases like “no significant FDG uptake,” “metabolically inactive,” “no hypermetabolic activity,” or simply “non-avid.” These all mean roughly the same thing: the area did not accumulate the tracer above background levels. Some reports will include the SUVmax number; others will use a descriptive scale ranging from no uptake to intense uptake.

A few things worth keeping in mind when you read the report:

  • Non-avid is not the same as normal: The radiologist is describing the metabolic behavior of a lesion, not declaring it benign. Other imaging features and clinical context still factor into the diagnosis.
  • Background uptake varies by organ: The brain and liver naturally absorb a lot of FDG, so a lesion in those organs needs to be considerably brighter to stand out. A small metastasis in the liver can be hidden by the organ’s normal background activity.
  • Timing after treatment matters: If you had chemotherapy or radiation recently, treated tumors may appear non-avid because the cancer cells have been killed or stunned. That is usually the hoped-for result, but your oncologist will still want follow-up scans to make sure the response holds.
  • The scan has known blind spots: If your cancer type is one that tends to be non-FDG avid (prostate, low-grade neuroendocrine, mucinous), your care team is aware of that and will not rely on FDG-PET alone. They may order one of the specialized tracers described above or use other imaging entirely.

If you are unsure what a non-FDG avid finding means for your particular situation, the most productive question to ask your doctor is not “is it cancer?” but rather “does this finding change what we do next?” That reframes the conversation around clinical action, which is where the answer usually lives.